BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 14619529)

  • 1. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer].
    Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
    Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
    Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Significance of CA72-4 as a follow up of recurrent gastric cancer--comparison with CEA and CA19-9].
    Takahashi Y; Mai M
    Gan To Kagaku Ryoho; 1992 Apr; 19(4):515-8. PubMed ID: 1558402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
    Zhu YB; Ge SH; Zhang LH; Wang XH; Xing XF; DU H; Hu Y; Li YA; Jia YN; Lin Y; Fan B; Ji JF
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Feb; 15(2):161-4. PubMed ID: 22368025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    Sun Z; Zhang N
    World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M; Dilege E; Demir U; Coskun H; Eroglu T; Uysalol MD
    Hepatogastroenterology; 2004; 51(59):1544-7. PubMed ID: 15362797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW; Jiang B; Han CZ; Jing JX
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
    Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
    Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between positive CA 72-4 serum levels and lymph node involvement in patients with gastric carcinoma.
    Guadagni F; Roselli M; Cosimelli M; Ferroni P; Spila A; Casaldi V; Cavaliere F; Carlini M; Garofalo A; Rinaldi G
    Anticancer Res; 1993; 13(6B):2409-13. PubMed ID: 8135475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
    Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
    Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of serum CEA, CA19-9 and CA72.4 in early diagnosis of recurrence after radical resection of gastric cancer.
    Li Y; Yang Y; Lu M; Shen L
    Hepatogastroenterology; 2011; 58(112):2166-70. PubMed ID: 22024091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
    Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
    J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
    Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
    Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of Preoperative Serum Levels of Five Tumor Markers (Carcinoembryonic Antigen, CA19-9, Alpha-fetoprotein, CA72-4, and CA125) in Gastric Cancer.
    Kim JH; Jun KH; Jung H; Park IS; Chin HM
    Hepatogastroenterology; 2014 May; 61(131):863-9. PubMed ID: 26176088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor markers in staging and prognosis of colorectal carcinoma.
    Levy M; Visokai V; Lipska L; Topolcan O
    Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-operative serum levels of CA72-4 in patients with gastric adenocarcinoma.
    Ikeguchi M; Katano K; Saitou H; Tsujitani S; Maeta M; Kaibara N
    Hepatogastroenterology; 1997; 44(15):866-71. PubMed ID: 9222706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
    Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
    Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
    Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
    Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.